Davis Polk advised the joint book-running managers in connection with a $190 million SEC-registered common stock offering of 6,139,515 shares of common stock of Revance Therapeutics,…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now